December 10, 2025 landed quietly, but Inito does not do small moments. A $29M Series B, led by Bertelsmann India Investments with Fireside Ventures returning, is not a headline grab. It is a checkpoint. Founded in 2015 by Aayush Rai and Varun AV, Inito waited until 2021 to launch a product. Six years of building before selling, which in startup math is either reckless or disciplined depending on whether you understand hardware, biology, and trust. The market is now answering that question for them.
Inito operates where healthcare stops being abstract and starts being personal. A smartphone-connected flat-lens reader, a single diagnostic strip, and suddenly estrogen, LH, PdG, and FSH stop acting like medical trivia and start behaving like usable data. Quantitative results, not yes-or-no theater. AI-driven interpretation, not vibes. That approach has supported tens of thousands of pregnancies and processed more than $30M hormone data points globally since launch, mostly without shouting about it.
Aayush Rai runs the company with the calm of someone who understands that credibility compounds slower than hype but lasts longer. Varun AV lives in the details, leading the flat-lens optical stack and pushing into AI-engineered synthetic antibodies designed to replace animal-derived components. That work is not flashy, but it is how you get consistency, scalability, and shelf stability at medical-grade levels. FDA Class II clearance does not happen because a deck looked good. A 95% user satisfaction rate does not come from clever copy.
The company is built like its product. Engineering, operations, and manufacturing anchored in Bengaluru. Commercial leadership based in San Francisco. Teams forming in London and Dubai. The geography tells the strategy without saying a word. FY24 revenue reached roughly ₹53.2 crore, profitability followed, and the direct-to-consumer engine runs through the Inito website and Amazon, with clinic integrations expanding quietly alongside it.
Swati Murarka and the Bertelsmann India Investments team did not lead this round to fund a fertility accessory. Fireside Ventures, with VS Kannan Sitaram continuing the partnership from Series A, did not double down for nostalgia. This is a bet on a platform. Fertility is the front door, not the whole house. Thyroid, Vitamin D, testosterone, cholesterol, pregnancy progression, menopause monitoring all sit on the same foundation: lab-grade diagnostics that live at home and scale across a lifetime.
Startups Startup Funding Venture Capital Series B AI Diagnostic Women Health Healthcare Health Tech Data Data Driven Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring
